Skip to content
    Clinical Trials

    Low-Dose Cyclophosphamide Maintenance Does Not Increase Second Malignancy Risk in RMS

    Bisogno et alCancer

    Low-Dose Cyclophosphamide Maintenance Does Not Increase Second Malignancy Risk in RMS
    In an analysis of 1633 patients enrolled in the European RMS 2005 trial, maintenance chemotherapy with low-dose cyclophosphamide and vinorelbine was not associated with an increased risk of second malignant neoplasms (SMNs). While the addition of maintenance chemotherapy has improved survival outcomes for patients with high-risk pediatric rhabdomyosarcoma, concerns existed regarding cumulative exposure to alkylating agents.
    At a median follow-up of 9.3 years (range, 0.6–17.7 years), 27 patients (1.7%) developed an SMN. SMNs occurred in 9 of 486 patients (1.9%) who received maintenance therapy compared to 17 of 1081 patients (1.6%) who did not receive maintenance (p = .75). The 8-year cumulative incidence of SMN across the overall cohort was estimated at 1.3% (95% CI, 0.8–2.0) using competing risk methodology.
    Osteosarcoma was the most frequent SMN (n = 6), followed by low-grade glioma (n = 3), hematological malignancies (n = 3), and undifferentiated sarcoma (n = 2). Twenty of the 27 patients with an SMN received radiotherapy prior to SMN development, including 8 patients whose SMN developed within a previously irradiated field.
    Genetic predisposition was identified as a major contributor to SMN development. Eight of the 27 patients had a known cancer predisposition syndrome, including Li-Fraumeni syndrome (LFS) in 6 patients and neurofibromatosis type 1 (NF1) in 2 patients; 3 of the 8 patients whose SMN arose in an irradiated field had LFS. The authors note that these findings support risk-adapted survivorship care and emphasize that longer follow-up is required to evaluate late-occurring SMNs.

    Key Takeaways

    • Maintenance chemotherapy was not associated with an increased risk of second malignant neoplasms compared to no maintenance therapy (1.9% [9 of 486] vs 1.6% [17 of 1081]; p = .75).
    • The 8-year cumulative incidence of second malignant neoplasms was 1.3% (95% CI, 0.8–2.0) across the entire cohort, with known cancer predisposition syndromes identified in 8 of the 27 affected patients (Li-Fraumeni syndrome in 6, neurofibromatosis type 1 in 2).